Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations

Kenjiro Kami, Yasunori Fujita, Saori Igarashi, Sayaka Koike, Shoko Sugawara, Satsuki Ikeda, Naomi Sato, Masafumi Ito, Masashi Tanaka, Masaru Tomita, Tomoyoshi Soga

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pyruvate treatment was found to alleviate clinical symptoms of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome and is highly promising therapeutic. Using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS), we measured time-changes of 161 intracellular and 85 medium metabolites to elucidate metabolic effects of pyruvate treatment on cybrid human 143B osteosarcoma cells harboring normal (2SA) and MELAS mutant (2SD) mitochondria. The results demonstrated dramatic and sustainable effects of pyruvate administration on the energy metabolism of 2SD cells, corroborating pyruvate as a metabolically rational treatment regimen for improving symptoms associated with MELAS and possibly other mitochondrial diseases.

Original languageEnglish
Pages (from-to)644-653
Number of pages10
JournalMitochondrion
Volume12
Issue number6
DOIs
Publication statusPublished - 2012 Nov 1

Keywords

  • CE-MS
  • Cybrid
  • Energy metabolism
  • MELAS
  • Metabolome
  • Pyruvate

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations'. Together they form a unique fingerprint.

  • Cite this

    Kami, K., Fujita, Y., Igarashi, S., Koike, S., Sugawara, S., Ikeda, S., Sato, N., Ito, M., Tanaka, M., Tomita, M., & Soga, T. (2012). Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations. Mitochondrion, 12(6), 644-653. https://doi.org/10.1016/j.mito.2012.07.113